Business Context and Reporting Period
Company: Natural Alternatives International, Inc. (NAI)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: December 31, 2009 (First half of Fiscal Year 2010)
Business Overview: NAI operates two primary segments: private label contract manufacturing (providing services for nutritional supplements) and branded products (Pathway to Healing line). The company recently divested its legacy Real Health Laboratories (RHL) business, which is now reported as discontinued operations.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Dec 31, 2009 | Six Months Ended Dec 31, 2009 |
|---|---|---|
| Net Sales | $17,249 | $34,210 |
| Gross Profit | $2,470 | $5,625 |
| Gross Margin | 14.3% | 16.4% |
| Operating Income (Continuing Ops) | $736 | $2,143 |
| Net Income (Total) | $674 | $2,015 |
| Cash and Cash Equivalents | $4,553 | $4,553 (Balance Sheet) |
| Total Debt (Outstanding) | $675 | $675 (Balance Sheet) |
| Operating Cash Flow | N/A | $2,231 |
Material Changes vs. Prior Period
- Revenue: Net sales for the six months ended Dec 31, 2009, decreased 7.9% to $34.2 million compared to $37.1 million in the prior year. Private label contract manufacturing sales declined 7.5%, while branded products sales dropped 18.3%.
- Profitability: The company returned to profitability, reporting a net income of $2.0 million for the six-month period, a significant turnaround from a net loss of $4.7 million in the same period of the prior year. Operating income from continuing operations improved from a loss of $2.3 million to a profit of $2.1 million.
- Margins: Gross profit margin expanded significantly to 16.4% (from 8.5% in the prior year) due to cost reduction programs, reduced labor costs, and a favorable shift in sales mix.
- Discontinued Operations: The legacy RHL business was sold. The company recorded a small loss on the sale of remaining assets ($6,000) but eliminated the earn-out provision previously attached to the deal.
Guidance, Outlook, and Risks
- Outlook: Management expects net sales and operating income for the third quarter of Fiscal 2010 to be lower than the comparable prior year period due to uncertain economic conditions and anticipated reduced sales volumes/pricing from largest customers.
- Strategic Initiatives: Plans include re-launching the Pathway to Healing product line with new formulations in late Fiscal 2010 and increasing marketing efforts for Dr. Cherry's brand. The company aims to diversify its customer base to reduce concentration risk.
- Liquidity: The company holds $4.6 million in cash and has $3.8 million available under its working capital line of credit. Management believes this is sufficient to fund operations for the next 12 months.
- Risks:
- Customer Concentration: Revenue concentration risk is high; the two largest customers accounted for 84% of total net sales in the first six months of Fiscal 2010.
- Branded Product Decline: The cessation of Dr. Cherry's television program in 2007 continues to negatively impact the acquisition of new customers for the branded segment.
- Supplier Dependency: The company relies on a limited number of raw material suppliers.
Investor Verification Checklist
- Customer Concentration: Verify the stability of relationships with the top two customers, who represent 84% of revenue.
- Discontinued Operations: Confirm the final status of the RHL asset sale and ensure no hidden liabilities remain from the indemnity guarantee (capped at $500,000).
- Branded Segment Turnaround: Monitor the success of the planned late-Fiscal 2010 re-launch of the Pathway to Healing product line.
- Debt Covenants: Review compliance with the $8.2 million credit facility covenants, particularly regarding working capital and interest coverage.
- Foreign Operations: Assess the impact of foreign exchange fluctuations on the European subsidiary (NAIE), which contributes significantly to non-U.S. sales.